Journal Article

DKFZ-2022-00877

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Using Circulating Tumor DNA To Guide Adjuvant Therapy in Bladder Cancer: IMvigor010 and IMvigor011

Grunewald, C. M. ; Niegisch, G. ; Albers, P. (Last author)DKFZ*

2022
Elsevier Amsterdam

This record in other databases:  

Please use a persistent id in citations: doi:10.1016/j.euf.2022.04.001

Note: #LA:C130# / 2022 May;8(3):646-647 / Note

---

Contributing Institute(s):

1. Personalisierte Früherkennung des Prostatakarzinoms (C130)

Research Program(s):

1. 313 - Krebsrisikofaktoren und Prävention (POF4-313) (POF4-313)

Appears in the scientific report 2022

---

Database coverage:
; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Essential Science Indicators ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---